This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Stroke, Volume 56, Issue Suppl_1 , Page AWMP18-AWMP18, February 1, 2025. Background:Cerebral microbleeds (CMBs) are associated with incident dementia, but the impact of specific CMB patterns is unclear. Compared to individuals with no CMBs, presence of any CMBs was associated with an increased risk of dementia (Table 2).
Stroke, Volume 55, Issue Suppl_1 , Page AWMP13-AWMP13, February 1, 2024. Introduction:Associations between magnetic resonance imaging (MRI) markers of vascular pathology and dementia risk in older adults have been established, but it remains less clear how lifestyle factors may modify this association. years) with ongoing surveillance.
Stroke, Volume 56, Issue Suppl_1 , Page ADP13-ADP13, February 1, 2025. Background:People with stroke are at high risk of dementia. Using linked administrative databases, we identified all 90-day dementia-free survivors of first acute ischemic stroke or intracerebral hemorrhage (ICH).
This misinformation would have resulted in many thousands of people giving up their medication and suffering heart attacks and strokes as a result. Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M With thousands dying. I make no claim to be Nostradamus 2.0.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content